LOS ANGELES (April 11, 2018) 41 patients from 12 states nationwide who are living with HIV or AIDS or were on PrEP filed a personal injury lawsuit against …
Louisiana HIV Patients file Federal Personal Injury Cases Against Gilead Over Key HIV Drug
Legal actions filed by two patients with HIV from Louisiana targets Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s …
Gilead Lawsuits: California HIV Patients File Class Action and Personal Injury Cases Over Key HIV Drug
By Ged Kenslea, AHF Newsroom Legal actions filed by patients with HIV from Los Angeles, San Diego & Marin Counties target Gilead over its promotion of HIV/AIDS medication that causes permanent …
‘Shameless’ Gilead Hikes Key AIDS Drug Pricing 6.9% Despite Recent Patent Expiration
As of January 2018, Gilead has raised the price of its HIV/AIDS treatments Truvada, Genvoya and Descovy 6.9%, despite the fact that the patent for tenofovir, a key component of …
As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada
Ethically challenged drug company has made billions off the drug since its initial FDA approval while it simultaneously sought to ‘evergreen’ and manipulate patent extension process LOS ANGELES (October 17, …
Fierce Pharma: Planes, hearses and caravans dot ‘Gilead Greed Kills!’ protests from AIDS foundation
By Carly Helfand | FiercePharma | Jun 16, 2016 The Los Angeles-based AIDS Healthcare Foundation has already sued Gilead Sciences and asked lawmakers to investigate the company over its drug pricing. …
AHF Calls on FDA, Congress to Investigate Gilead Sciences Over HIV/AIDS Drug Patent Manipulation
Blistering Los Angeles Times news article exposes Gilead’s bald-faced greed, patent manipulation and disregard for patient safety re: two formulations of a key AIDS drug used by as many as …
LA Times: A question of timing – A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner
By Melody Petersen | Los Angeles Times | May 29, 2016 More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the …
AHF Seeks Partners to Distribute Standalone Version of Tenofovir (TAF); Files Amended Federal Complaint Against Gilead Over Disputed AIDS Drug Patent
In January, AHF filed a federal lawsuit against Gilead Sciences, Inc. and two other defendants alleging drug patent manipulation and anti-trust claims regarding slightly different formulations of tenofovir, a key …
AHF: Gilead Says it “Had No Duty to Develop” Less Harmful AIDS Drug in Legal Motion on Patent Lawsuit
In January, AHF filed a federal lawsuit against Gilead Sciences, Inc. and two other defendants alleging drug patent manipulation and anti-trust claims regarding Genvoya, Gilead’s new four-in-one Fixed Dose Combination …